Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;45(11):1590-1598.
doi: 10.1007/s00270-022-03206-y. Epub 2022 Aug 2.

Role of Radioembolization in Metastatic Neuroendocrine Tumors

Robert J Lewandowski  1 , Beau B Toskich  2 , Daniel B Brown  3 , Ghassan El-Haddad  4 , Siddharth A Padia  5
Affiliations
Review

Role of Radioembolization in Metastatic Neuroendocrine Tumors

Robert J Lewandowski et al. Cardiovasc Intervent Radiol. 2022 Nov.

Abstract

The liver is the most common site of metastasis for neuroendocrine tumors originating from the gastrointestinal tract. Neuroendocrine liver metastases (NELMs) portend a worsening clinical course, making local management important. Local treatment options include surgery, thermal ablation, and trans-catheter intra-arterial therapies, such as radioembolization. Radioembolization is generally preferred over other embolotherapies in patients with colonized biliary systems. Current best practice involves personalized treatment planning, optimizing tumor radiation absorbed dose and minimizing radiation to the normal hepatic parenchyma. As part of a multidisciplinary approach, radioembolization is a versatile embolotherapy offering neoadjuvant, palliative, and ablative treatment options for patients with NELMs.

Keywords: Neuroendocrine liver metastases (NELMs); Radioembolization; Yttrium-90 (Y90).

PubMed Disclaimer

References

    1. Pavel M, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76. - PubMed
    1. Yao JC, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. - PubMed
    1. Janson ET, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685–90. - PubMed
    1. Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer. 2015;121(8):1172–86. - PubMed
    1. Dasari A, et al. Trends in the Incidence, prevalence, and survival outcomes in patients With neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources